Diabetes, Vol 47, Issue 1 50-56, Copyright © 1998 by American Diabetes Association
GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice
Z Wang and H Gleichmann
Clinical Experimental Department, Diabetes Research Institute, Heinrich-Heine University of Dusseldorf, Germany.
In mice, diabetes can be induced by multiple low doses of streptozotocin
(MLD-STZ), i.e., 40 mg/kg body wt on each of 5 consecutive days. In this
model, diabetes develops only when STZ induces both beta-cell toxicity and
T-cell-dependent immune reactions. The target molecule(s) of
MLD-STZ-induced beta-cell toxicity are not known, however. In this study,
we report that GLUT2 is a target molecule for MLD-STZ toxicity. Ex vivo, a
gradual decrement of both GLUT2 protein and mRNA expression was found in
pancreatic islets isolated from MLD-STZ-treated C57BL/6 male mice, whereas
mRNA expression of beta-actin, glucokinase, and proinsulin remained
unaffected. Significant reduction of both GLUT2 protein and mRNA expression
was first noted 1 day after the third STZ injection, clearly preceding the
onset of hyperglycemia. The extent of reduction increased with the number
of STZ injections administered and increased over time, after the last,
i.e., fifth, STZ injection. The STZ-induced reduction of GLUT2 protein and
mRNA was not due to an essential loss of beta-cells, because ex vivo, not
only the total RNA yield and protein content in isolated islets, but also
proinsulin mRNA expression, failed to differ significantly in the
differently treated groups. Furthermore, islets isolated from
MLD-STZ-treated donors responded to the nonglucose secretagogue arginine in
a pattern similar to that of solvent-treated donors. Interestingly, the
MLD-STZ-induced reduction of both GLUT2 protein and mRNA was prevented by
preinjecting mice with 5-thio-D-glucose before each STZ injection.
Apparently, GLUT2 is a crucial target molecule of MLD-STZ toxicity, and
this toxicity seems to precede the immune reactions against beta-cells.